0001209191-19-015896.txt : 20190304 0001209191-19-015896.hdr.sgml : 20190304 20190304181227 ACCESSION NUMBER: 0001209191-19-015896 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190228 FILED AS OF DATE: 20190304 DATE AS OF CHANGE: 20190304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WU JINN CENTRAL INDEX KEY: 0001314254 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38112 FILM NUMBER: 19655671 MAIL ADDRESS: STREET 1: 107 MORGAN LANE CITY: PLAINSBORO STATE: NJ ZIP: 08536 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Athenex, Inc. CENTRAL INDEX KEY: 0001300699 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 431985966 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 BUSINESS PHONE: 716-898-8625 MAIL ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20131223 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC DATE OF NAME CHANGE: 20040817 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-28 0 0001300699 Athenex, Inc. ATNX 0001314254 WU JINN C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600 BUFFALO NY 14203 1 0 0 0 Common Stock 321208 D Stock Option (Right to Buy) 4.55 2013-01-02 2023-01-02 Common Stock 90000 90000 D Stock Option (Right to Buy) 4.55 2014-02-12 2024-02-12 Common Stock 10000 10000 D Stock Option (Right to Buy) 5.50 2015-02-05 2025-02-05 Common Stock 54000 54000 D Stock Option (Right to Buy) 5.50 2017-03-20 2025-03-20 Common Stock 96000 96000 D Stock Option (Right to Buy) 11.00 2027-06-13 Common Stock 28500 28500 D Stock Option (Right to Buy) 13.17 2019-02-28 4 A 0 15000 0.00 A 2029-02-28 Common Stock 15000 15000 D The option vests in four equal annual installments beginning on June 13, 2018. The option vests in four equal annual installments beginning on February 28, 2020. /s/ Teresa Bair, Attorney-in-Fact 2019-03-04